Cardiovascular morbidity and mortality are very common in patients with chronic kidney disease, which may result in part from vascular calcification. Vascular calcification requires osteoblastic trans-differentiation of vascular smooth muscle cells through an active and highly regulated process that is morphologically and functionally similar to bone formation in a number of ways. Multiple studies have been published on this topic, but the precise mechanism of vascular calcification remains unclear. This review presents recent insights into the mechanism of vascular calcification, as well as therapies that modulate mineral metabolism. 
. Pathophysiology and therapeutic approach for vascular calcification in CKD. Trans-differentiation of vascular smooth muscle cells into osteoblast-like cells is the most important step in vascular calcification. In the CKD environment, dysregulated minerals form complex crystals with reduction of calcification inhibitors at the matrix-degraded area in the diseased vessel. The current therapeutic approaches affecting each step are also described. VSMC, vascular smooth muscle cell; OB, osteoblast like cell; SMA, smooth muscle α -actin; SM22α, smooth muscle protein 22α; WNT, OPG, osteoprotegerin; RANK, receptor activator of NF-κB; RANKL, RANK ligand; RUNX2, runt related transcription factor 2; Cbfa1, core-binding factor α 1; MMP, matrix metalloprotease; CPP, calciprotein particle; Ca, calcium; P, phosphate; MGP, matrix Gla protein; OPN, osteopontin; FGF-23, fibroblast growth factor-23; OPG, osteoprotegerin; PTH, parathyroid hormone; NCPB, non-calcium based phosphate binder; CKD, chronic kidney disease. 
혈관세포외기질 소실(matrix degradation)
Elastin은 혈관벽에 가장 풍부하게 존재하는 단백 물질로, 만성 콩팥병 환경에서는 elastin의 소실이 흔하다 [19, 20] . 
